Doral, FL, Oct. 10, 2017 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC PINK: ETST) ("ETST" or "the Company"), an innovative biotech company that operates in the fields of hemp cannabinoid (CBD), nutraceutical, pharmaceutical, medical device, research and development, partners with La Clinique Santé Amitié - a Clinic Specialized in the Detection and Treatment of Sexually Transmitted Infections - for its Final Pre-Launch MSN-2 human research study.

ETST is proud to announce a new collaboration with the clinic of the Centre SIDA Amité (AIDS Friendship Centre) which specializes in the screening and treatment of people with sexually transmitted infections (STI). This collaboration will allow ETST to finalize the pre-launch stage of its new MSN-2 medical device. The mini-clinical trial is the last trial needed to allow for the launch of the MSN-2 device. This fine-tuning trials will be conducted with the participation of a Québec hospital that will be named in the next few days.

Michel Aubé PhD, CEO and Chief Scientific Officer of ETST, says “I am very pleased with this new partnership. We needed people with impeccable bona fides who are totally devoted to the cause of their patients. That is what we found in this dynamic team. They make a remarkable difference in the quality of life of people battling problems connected to STI and they are people with whom we share a vision."

The Clinique Santé Amitié  (Friendship Health Clinic) is a project by the same people who created the Clinique SIDA Amitié, a place of meeting and exchange whose mission is to support and to counsel people living with HIV/AIDS and viral hepatitis, as well as to increase public awareness and education of sexually transmitted infections.

The new MSN-2 medical device has the potential to decrease the spread of HIV by reducing the prevalence of chlamydia in young women. It is fact that when a woman is infected with chlamydia, her risk of contracting HIV is five times the risk of a woman who does not have chlamydia. In addition, chlamydia is the main cause of female infertility in industrialized countries. An undiagnosed, asymptomatic chlamydia infection spreads through the reproductive organs and causes irreversible damage to the woman, requiring specialized care including hospitalization and the administration of intravenous antibiotics, and may have serious effects on any unborn child she is carrying.

Announced on early August, the branding exercise for the MSN-2 device is currently being conducted by Absolu Agency and will be completed in November 2017. ETST is confident that the device will be market-ready as early as Q1 2018. The company’s existing manufacturing facility will be completely reorganized toward the end of November after which will be able to produce up to 10,000 MSN-2 units a week, a production rate that can be increased as needed to meet demand.

Nickolas S. Tabraue, ETST's President, Director, & COO ends with, “We currently have all our partners - Canadian, American, and world-wide looking forward to the launch of the new MSN-2 device for women. Thanks to Dr. Aube’s amazing work we plan on delivering the first sample kits before year-end and plan on sharing updates as they progress as well as many other exciting updates on our patents, KannaBidioiD subsidiary, distribution, education strategy, and expansion.”

About Earth Science Tech, Inc. (ETST): Earth Science Tech has the highest quality, purity, and full spectrum High Grade Hemp CBD (Cannabidiol) Oil on the market. Made using the world's best supercritical CO2 liquid extraction, our CBD Oil is 100% natural and organic. Our research performed alongside the University of Central Oklahoma and DV Biologics laboratory, prove we are the top nutritional and dietary supplement brand for High Grade Hemp CBD Oil. 

To learn more and to buy CBD Hemp Oil please visit:

View ETST's accomplishments and reports on its High-Grade CBD Hemp Oil: (here)

About Earth Science Pharmaceutical: Earth Science Pharmaceutical, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc (ETST). Earth Science Pharmaceutical is focused on becoming a world leader in the development of low cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for STIs (Sexually Transmitted Infections and/or Diseases). Earth Science Pharmaceutical CEO, Dr. Michel Aubé, a renowned scientist, is committed to help grow ETST in the medical and pharmaceutical industry.

To learn more please visit:

About Cannabis Therapeutics: Cannabis Therapeutics, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc. (ETST). Cannabis Therapeutics, Inc. was formed as an emerging biotechnology company poised to become a world leader in cannabinoid research and development for a broad line of cannabis cannabinoid-based pharmaceuticals, nutraceuticals as well as other products & solutions. Cannabis Therapeutics mission it to help change the healthcare landscape by introducing their proprietary cannabis-cannabinoid based products made for both the pharmaceutical and retail consumer markets worldwide.

To learn more please visit:

About KannaBidioiD: KannaBidioid, Inc. is wholly owned subsidiary of Earth Science Tech, Inc. (ETST). KannaBidioid, Inc. is focused in the recreational space to manufacture and distribute vapes/e-liquids and gummy edibles in the recreational space formulated by it's unique Kanna and CBD formula. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhance focus, and help with nicotine addiction based on their properties.

To learn more please visit:

FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE: These statements and products have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. Always check with your physician before starting a new dietary supplement program. The FDA has not evaluated the validity or truthfulness of these claims; therefore, we encourage you to review published researches relating to the benefits and properties of CBD hemp oils and other CBD products.

SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations 
Dave Demarest 

Earth Science Tech, Inc. 
Nickolas S. Tabraue, P/D/COO